Clinical Trial Detail

NCT ID NCT01976741
Title Phase I Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements yes
Sponsors Bayer
Indications

lung adenocarcinoma

lung non-small cell carcinoma

lung squamous cell carcinoma

urinary bladder cancer

head and neck cancer

Advanced Solid Tumor

Therapies

Rogaratinib

Age Groups: adult senior

Additional content available in CKB BOOST